MONDAY, June 8, 2026 (HealthDay News) -- Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with reduced risks for thromboembolic events, emergency department use, and mortality among adults with obesity and autoimmune diseases (AIDs), according to a study published online June 6 in the Journal of the American Heart Association to coincide with the annual meeting of the American Diabetes Association, held from June 5 to 8 in New Orleans.Hao Dai, Ph.D., from the Indiana University School of Medicine in Indianapolis, and colleagues conducted a retrospective cohort study, which emulated a target trial using 2014 to 2024 electronic health record data to examine the association between GLP-1 RA use and major adverse cardiovascular and thromboembolic event risk among adults with obesity and AID
While exercise and muscle strengthening can help, plastic surgery offers definitive solutions for reshaping the body after substantial weight loss
This evidence highlights that a significant percentage of the global population resides in countries where overweight and obesity pose an urgent health risk, driving a surge in related conditions such as type 2 diabetes
While these studies are essential for advancing scientific understanding and can sometimes inform human biology, their results cannot be directly extrapolated to human physiology in a 1:1 manner
[DOI] [PMC free article] [PubMed] [Google Scholar] 183.Luo C., Peng Y., Gu J., Li T., Wang Q., Qi X., Wei A
